The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.
 
Angela Wangari Walter
No Relationships to Disclose
 
Ju-Whei Lee
No Relationships to Disclose
 
Ilana F. Gareen
No Relationships to Disclose
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Benjamin A. Herman
No Relationships to Disclose
 
Joanna M. Streck
No Relationships to Disclose
 
Shaji Kumar
Honoraria - BeiGene
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Cellectar; Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Ingrid A. Mayer
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Cyclacel; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Nabil F. Saba
Honoraria - BioNTech; CUE Biopharma; Merck
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Blueprint Medicines; GlaxoSmithKline; Merck; Pfizer
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Natera; Regeneron; Sanofi/Regeneron; Surface Oncology; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - Amgen; Bioentre; Boston Pharmaceuticals; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Torque; Trillium Therapeutics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Christos Kyriakopoulos
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Janssen Oncology; Sanofi
Research Funding - Sanofi
 
Clare Tempany
Stock and Other Ownership Interests - F-Star Biotechnology (I); Promaxo
Honoraria - Medscape
Consulting or Advisory Role - Profound Medical
Speakers' Bureau - Medscape
Research Funding - Gilead Sciences; InSightec (Inst)
 
Tait D. Shanafelt
Honoraria - Multiple Healthcare organizations
Research Funding - Celgene (Inst); Cephalon (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hospira (Inst); Pharmacyclics (Inst); Polyphenon E International (Inst)
Patents, Royalties, Other Intellectual Property - Dr. Shanafelt is co-inventor of the Well-being Index Instruments (Physician Well-being Index; Nurse Well-being Index; Medical Student Well-being Index; Well-being Index) and the Mayo Clinic Participatory Management Leadership Index. Mayo Clinic holds the
 
Lynne I. Wagner
Stock and Other Ownership Interests - Gilead Sciences (I); Johnson & Johnson (I); Lilly (I)
Consulting or Advisory Role - Athenex; Celgene
Travel, Accommodations, Expenses - Celgene
 
Stephanie R. Land
No Relationships to Disclose
 
Jamie S. Ostroff
Patents, Royalties, Other Intellectual Property - UptoDate
 
Elyse R. Park
Honoraria - UpToDate